CD86 and plasma cell myeloma: Our group demonstrated that the binding of CD28 expressed on myeloma plasma cells with its ligands CD80/CD86 expressed on BM dendritic cells (DCs) results in downregulation of the expression of proteasome subunits, alteration of the antigen repertoire displayed on myeloma plasma cell surface, and reduced recognition of tumor plasma cells by cytotoxic CD8+ T cells (10).